The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model

吞噬受体锚定激动剂在癌症免疫治疗中的应用:B16-F10 小鼠黑色素瘤模型

阅读:6
作者:Tereza Janotová, Marie Jalovecká, Marie Auerová, Ivana Švecová, Pavlína Bruzlová, Veronika Maierová, Zuzana Kumžáková, Štěpánka Cunátová, Zuzana Vlčková, Veronika Caisová, Petra Rozsypalová, Katarína Lukáčová, Nikol Vácová, Markéta Wachtlová, Jiří Salát, Jaroslava Lieskovská, Jan Kopecký, Jan Ženka

Abstract

The application of the phagocytic receptor agonists in cancer immunotherapy was studied. Agonists (laminarin, molecules with terminal mannose, N-Formyl-methioninyl-leucyl-phenylalanine) were firmly anchored to the tumor cell surface. When particular agonists of phagocytic receptors were used together with LPS (Toll-like receptor agonist), high synergy causing tumour shrinkage and a temporary or permanent disappearance was observed. Methods of anchoring phagocytic receptor agonists (charge interactions, anchoring based on hydrophobic chains, covalent bonds) and various regimes of phagocytic agonist/LPS mixture applications were tested to achieve maximum therapeutic effect. Combinations of mannan/LPS and f-MLF/LPS (hydrophobic anchors) in appropriate (pulse) regimes resulted in an 80% and 60% recovery for mice, respectively. We propose that substantial synergy between agonists of phagocytic and Toll-like receptors (TLR) is based on two events. The TLR ligand induces early and massive inflammatory infiltration of tumors. The effect of this cell infiltrate is directed towards tumor cells, bearing agonists of phagocytic receptors on their surface. The result of these processes was effective killing of tumor cells. This novel approach represents exploitation of innate immunity mechanisms for treating cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。